From USA TODAY Network and wire reports
Alabama
Tuscaloosa: Students across the three-campus University of Alabama System will return to in-person instruction for the fall semester with no limits on class size in Birmingham, Huntsville or Tuscaloosa to guard against COVID-19, officials said Monday. The system, which has held classes in multiple formats since the pandemic began a year ago, said in a statement that current models show it should be safe to resume traditional teaching after the summer break. Millions more should have been vaccinated against the disease by then. Dr. Selwyn Vickers, the medical dean at the University of Alabama at Birmingham and chair of the system’s pandemic task force, said leaders will continue trying to make decisions based on data and guidance from the Centers for Disease Control and Prevention and the state health agency. “If safety concerns arise, we can adjust our plan; the safety of the 110,000 students, faculty and staff of the UA System re
J&J vaccine could be a game changer But the rollout comes with some risks msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
This $285 eye scan may someday detect Alzheimer s risk. (It also requires plenty of curry flavoring.)
⋮
Researchers have long sought ways to predict whether a patient will develop Alzheimer s or Parkinson s disease, but their current options are costly and impractical. Now, they re exploring whether an inexpensive picture of a patient s eye could accurately assess risk, the
Washington Post s Elizabeth Brown reports.
A need for early detection
Experts and providers say that early detection of a patient s risk for neurodegenerative diseases could support advance planning and potentially help researchers develop treatments.
Early detection is sort of the holy grail, Ron Petersen, director of
Genkyotex: Disclosure of the total number of voting rights and shares pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority
Regulatory News:
Genkyotex shares
Date
(1): 11,736,174
(2): 11,726,931
(1)
In accordance with Article 223-111 of the AMF s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
(2)
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. Its unique platform enables the identification of orally available small-molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex is developing a pipeline of first-in-class product candidates targeting